

# David S Goldfarb

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6804935/publications.pdf>

Version: 2024-02-01

235  
papers

10,027  
citations

34105

52  
h-index

43889

91  
g-index

270  
all docs

270  
docs citations

270  
times ranked

9034  
citing authors

#	ARTICLE	IF	CITATIONS
1	Medical Management of Kidney Stones: AUA Guideline. <i>Journal of Urology</i> , 2014, 192, 316-324.	0.4	692
2	Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 1163.	7.4	405
3	Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment. <i>Nature Communications</i> , 2015, 6, 7486.	12.8	317
4	Subcutaneous Compared with Intravenous Epoetin in Patients Receiving Hemodialysis. <i>New England Journal of Medicine</i> , 1998, 339, 578-583.	27.0	292
5	A twin study of genetic and dietary influences on nephrolithiasis: A report from the Vietnam Era Twin (VET) Registry. <i>Kidney International</i> , 2005, 67, 1053-1061.	5.2	226
6	Randomized Controlled Trial of Clopidogrel plus Aspirin to Prevent Hemodialysis Access Graft Thrombosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2313-2321.	6.1	221
7	Hereditary causes of kidney stones and chronic kidney disease. <i>Pediatric Nephrology</i> , 2013, 28, 1923-1942.	1.7	213
8	Crystal Growth Inhibitors for the Prevention of <sc> </sc> -Cystine Kidney Stones Through Molecular Design. <i>Science</i> , 2010, 330, 337-341.	12.6	212
9	KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. <i>American Journal of Kidney Diseases</i> , 2013, 62, 849-859.	1.9	206
10	Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. <i>Advances in Therapy</i> , 2010, 27, 634-647.	2.9	189
11	Pathophysiology and treatment of cystinuria. <i>Nature Reviews Nephrology</i> , 2010, 6, 424-434.	9.6	183
12	Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. <i>Journal of Applied Physiology</i> , 2007, 102, 1313-1322.	2.5	172
13	Prevalence of Contraindications and Prescription of Pharmacologic Therapies for Gout. <i>American Journal of Medicine</i> , 2011, 124, 155-163.	1.5	168
14	The Association of Nephrolithiasis With Hypertension and Obesity: A Review. <i>American Journal of Hypertension</i> , 2008, 21, 257-264.	2.0	164
15	Use of a probiotic to decrease enteric hyperoxaluria. <i>Kidney International</i> , 2005, 68, 1244-1249.	5.2	151
16	Twice-Weekly and Incremental Hemodialysis Treatment for Initiation of Kidney Replacement Therapy. <i>American Journal of Kidney Diseases</i> , 2014, 64, 181-186.	1.9	144
17	Nutrient Non-equivalence: Does Restricting High-Potassium Plant Foods Help to Prevent Hyperkalemia in Hemodialysis Patients?. , 2016, 26, 282-287.		137
18	Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. <i>Kidney International</i> , 2010, 78, 1178-1185.	5.2	128

#	ARTICLE	IF	CITATIONS
19	Extracorporeal Treatment for Lithium Poisoning. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 875-887.	4.5	128
20	Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney International, 2009, 75, 15-24.	5.2	124
21	Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. Journal of Nephrology, 2016, 29, 715-734.	2.0	122
22	Ambient temperature as a contributor to kidney stone formation: implications of global warming. Kidney International, 2011, 79, 1178-1185.	5.2	116
23	Use of hemodialysis and hemoperfusion in poisoned patients. Kidney International, 2008, 74, 1327-1334.	5.2	110
24	Oral Antibiotic Exposure and Kidney Stone Disease. Journal of the American Society of Nephrology: JASN, 2018, 29, 1731-1740.	6.1	109
25	Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population Health. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1305-1312.	4.5	106
26	Cystinuria. Seminars in Nephrology, 2008, 28, 181-191.	1.6	104
27	The EXTRIP (<i>EXtracorporeal TReatments In Poisoning</i>) workgroup: Guideline methodology. Clinical Toxicology, 2012, 50, 403-413.	1.9	103
28	Impending Shortages of Kidney Replacement Therapy for COVID-19 Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 880-882.	4.5	101
29	Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. Annals of Emergency Medicine, 2015, 66, 165-181.	0.6	98
30	Melamine-related kidney stones and renal toxicity. Nature Reviews Nephrology, 2011, 7, 267-274.	9.6	97
31	Optimal Medical Therapy With or Without Percutaneous Coronary Intervention for Patients With Stable Coronary Artery Disease and Chronic Kidney Disease. American Journal of Cardiology, 2009, 104, 1647-1653.	1.6	94
32	Optimum Nutrition for Kidney Stone Disease. Advances in Chronic Kidney Disease, 2013, 20, 165-174.	1.4	94
33	CLINICAL USE OF CYSTINE SUPERSATURATION MEASUREMENTS. Journal of Urology, 2000, 164, 1481-1485.	0.4	93
34	Risk of Chronic and End Stage Kidney Disease in Patients with Nephrolithiasis. Journal of Urology, 2014, 192, 1440-1445.	0.4	92
35	The association of nephrolithiasis with cystic fibrosis. American Journal of Kidney Diseases, 2003, 42, 1-11.	1.9	88
36	The New Epidemiology of Nephrolithiasis. Advances in Chronic Kidney Disease, 2015, 22, 273-278.	1.4	87

#	ARTICLE	IF	CITATIONS
37	Enteric hyperoxaluria: an important cause of end-stage kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 375-382.	0.7	87
38	Immune complex glomerulonephritis in patients coinfectd with human immunodeficiency virus and hepatitis C virus. <i>American Journal of Kidney Diseases</i> , 1997, 29, 514-525.	1.9	85
39	A Randomized, Controlled Trial of Lactic Acid Bacteria for Idiopathic Hyperoxaluria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 745-749.	4.5	84
40	EFFECT OF GRAPEFRUIT JUICE ON URINARY LITHOGENICITY. <i>Journal of Urology</i> , 2001, 166, 263-267.	0.4	81
41	Surgical Decompression is Associated with Decreased Mortality in Patients with Sepsis and Ureteral Calculi. <i>Journal of Urology</i> , 2013, 189, 946-951.	0.4	81
42	Strategies for preventing calcium oxalate stones. <i>Cmaj</i> , 2006, 174, 1407-1409.	2.0	76
43	The role of the microbiome in kidney stone formation. <i>International Journal of Surgery</i> , 2016, 36, 607-612.	2.7	76
44	Increasing prevalence of kidney stones in the United States. <i>Kidney International</i> , 2003, 63, 1951-1952.	5.2	69
45	The Availability and Use of Charcoal Hemoperfusion in the Treatment of Poisoned Patients. <i>American Journal of Kidney Diseases</i> , 2006, 48, 239-241.	1.9	68
46	Effect of Vitamin D Repletion on Urinary Calcium Excretion among Kidney Stone Formers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 829-834.	4.5	68
47	Guidelines for Reporting Case Studies on Extracorporeal Treatments in Poisonings: Methodology. <i>Seminars in Dialysis</i> , 2014, 27, 407-414.	1.3	68
48	Urinary Lithogenic Risk Profile in Recurrent Stone Formers With Hyperoxaluria: A Randomized Controlled Trial Comparing DASH (Dietary Approaches to Stop Hypertension)-Style and Low-Oxalate Diets. <i>American Journal of Kidney Diseases</i> , 2014, 63, 456-463.	1.9	68
49	The Role of Continuous Renal Replacement Therapy in the Treatment of Poisoning. <i>Seminars in Dialysis</i> , 2006, 19, 402-407.	1.3	67
50	A Pilot Clinical Study to Evaluate Changes in Urine Osmolality and Urine cAMP in Response to Acute and Chronic Water Loading in Autosomal Dominant Polycystic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 693-697.	4.5	66
51	Homocysteine Lowering and Cognition in CKD: The Veterans Affairs Homocysteine Study. <i>American Journal of Kidney Diseases</i> , 2009, 54, 440-449.	1.9	64
52	The Role of the 24-Hour Urine Collection in the Prevention of Kidney Stone Recurrence. <i>Journal of Urology</i> , 2017, 197, 1084-1089.	0.4	57
53	Cystinuria: genetic aspects, mouse models, and a new approach to therapy. <i>Urolithiasis</i> , 2019, 47, 57-66.	2.0	57
54	Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1960-1967.	4.5	56

#	ARTICLE	IF	CITATIONS
55	Oral Antibiotic Treatment of <i>Helicobacter pylori</i> Leads to Persistently Reduced Intestinal Colonization Rates with <i>Oxalobacter formigenes</i> . <i>Journal of Endourology</i> , 2011, 25, 1781-1785.	2.1	55
56	Adverse Metabolic Side Effects of Thiazides: Implications for Patients With Calcium Nephrolithiasis. <i>Journal of Urology</i> , 2007, 177, 1238-1243.	0.4	54
57	Treatment of Pregabalin Toxicity by Hemodialysis in a Patient With Kidney Failure. <i>American Journal of Kidney Diseases</i> , 2009, 54, 1127-1130.	1.9	51
58	The Presence of <i>Oxalobacter formigenes</i> in the Microbiome of Healthy Young Adults. <i>Journal of Urology</i> , 2016, 195, 499-506.	0.4	51
59	Effect of Cystine-Binding Thiol Drugs on Urinary Cystine Capacity in Patients with Cystinuria. <i>Journal of Endourology</i> , 2005, 19, 429-432.	2.1	49
60	Extracorporeal Removal Techniques for the Poisoned Patient: A Review for the Intensivist. <i>Journal of Intensive Care Medicine</i> , 2010, 25, 139-148.	2.8	49
61	Citrate, Malate and Alkali Content in Commonly Consumed Diet Sodas: Implications for Nephrolithiasis Treatment. <i>Journal of Urology</i> , 2010, 183, 2419-2423.	0.4	47
62	Update on cystinuria. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 427-431.	2.0	47
63	Dialysis Initiation: What's the Rush?. <i>Seminars in Dialysis</i> , 2013, 26, 650-657.	1.3	45
64	Update on the Pathophysiology and Management of Uric Acid Renal Stones. <i>Current Rheumatology Reports</i> , 2010, 12, 125-129.	4.7	44
65	Amelioration of Renal Ischemia-Reperfusion Injury With a Novel Protective Cocktail. <i>Journal of Urology</i> , 2011, 186, 2448-2454.	0.4	43
66	Urine and stone analysis for the investigation of the renal stone former: a consensus conference. <i>Urolithiasis</i> , 2021, 49, 1-16.	2.0	43
67	Gout and its comorbidities. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2010, 68, 199-203.	0.7	42
68	Extracorporeal Treatment for Thallium Poisoning. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1682-1690.	4.5	41
69	Indications for Hospitalization of Patients With Hyperkalemia. <i>Archives of Internal Medicine</i> , 2000, 160, 1605.	3.8	39
70	A Woman with Recurrent Calcium Phosphate Kidney Stones. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1172-1178.	4.5	39
71	Assessment of the combination of temperature and relative humidity on kidney stone presentations. <i>Environmental Research</i> , 2018, 162, 97-105.	7.5	39
72	A Twin Study of Genetic Influences on Nephrolithiasis in Women and Men. <i>Kidney International Reports</i> , 2019, 4, 535-540.	0.8	39

#	ARTICLE	IF	CITATIONS
73	Ichthyotoxic ARF after fish gallbladder ingestion: a large case series from Vietnam. <i>American Journal of Kidney Diseases</i> , 2003, 41, 220-224.	1.9	38
74	Asymptomatic Nephrolithiasis Detected by Ultrasound. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 680-684.	4.5	38
75	Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors. <i>Journal of Rheumatology</i> , 2011, 38, 1385-1389.	2.0	37
76	Sex differences in the temperature dependence of kidney stone presentations: a population-based aggregated case-crossover study. <i>Urolithiasis</i> , 2020, 48, 37-46.	2.0	35
77	Health-related quality of life (HRQoL) in cystine compared with non-cystine stone formers. <i>Urolithiasis</i> , 2014, 42, 53-60.	2.0	34
78	A RANKL Wrinkle: Denosumab-Induced Hypocalcemia. <i>Journal of Medical Toxicology</i> , 2016, 12, 305-308.	1.5	34
79	Association of nephrolithiasis prevalence rates with ambient temperature in the United States: a re-analysis. <i>Kidney International</i> , 2009, 76, 798.	5.2	33
80	Cystine nephrolithiasis. <i>Translational Andrology and Urology</i> , 2014, 3, 228-233.	1.4	33
81	Diagnosis of Medullary Sponge Kidney by Computed Tomographic Urography. <i>American Journal of Kidney Diseases</i> , 2007, 50, 146-150.	1.9	32
82	Metabolic Evaluation of First-time and Recurrent Stone Formers. <i>Urologic Clinics of North America</i> , 2013, 40, 13-20.	1.8	32
83	A Nomogram for the Prediction of Kidney Stone Recurrence. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2685-2687.	6.1	32
84	Renal Replacement Therapy and Incremental Hemodialysis for Veterans with Advanced Chronic Kidney Disease. <i>Seminars in Dialysis</i> , 2017, 30, 251-261.	1.3	31
85	Effect of two sports drinks on urinary lithogenicity. <i>Urological Research</i> , 2009, 37, 41-46.	1.5	30
86	The underutilization of hemodialysis in patients with salicylate poisoning. <i>Kidney International</i> , 2009, 75, 1349-1353.	5.2	30
87	Continuous Renal Replacement Therapy Does Not Have a Clear Role in the Treatment of Poisoning. <i>Nephron Clinical Practice</i> , 2010, 115, c1-c6.	2.3	30
88	Potassium citrate decreases urine calcium excretion in patients with hypocitraturic calcium oxalate nephrolithiasis. <i>Urolithiasis</i> , 2016, 44, 145-148.	2.0	30
89	Empiric therapy for kidney stones. <i>Urolithiasis</i> , 2019, 47, 107-113.	2.0	30
90	Predictive Value of a Positive Fecal Occult Blood Test Increases as the Severity of CKD Worsens. <i>American Journal of Kidney Diseases</i> , 2006, 48, 580-586.	1.9	29

#	ARTICLE	IF	CITATIONS
91	Tamm-Horsfall protein/uromodulin deficiency elicits tubular compensatory responses leading to hypertension and hyperuricemia. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, F1062-F1076.	2.7	28
92	Microorganisms and Calcium Oxalate Stone Disease. <i>Nephron Physiology</i> , 2004, 98, p48-p54.	1.2	26
93	Comparison of the effect of allopurinol and febuxostat on urinary 2,8-dihydroxyadenine excretion in patients with Adenine phosphoribosyltransferase deficiency (APRTd): A clinical trial. <i>European Journal of Internal Medicine</i> , 2018, 48, 75-79.	2.2	26
94	Uric Acid Stones and Hyperuricosuria. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 413-418.	1.4	25
95	Evaluation and Medical Management of Patients with Cystine Nephrolithiasis: A Consensus Statement. <i>Journal of Endourology</i> , 2020, 34, 1103-1110.	2.1	25
96	Renal Stone Disease in Older Adults. <i>Clinics in Geriatric Medicine</i> , 1998, 14, 367-382.	2.6	24
97	Potential Pharmacologic Treatments for Cystinuria and for Calcium Stones Associated with Hyperuricosuria: Figure 1.. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2093-2097.	4.5	24
98	Diagnostic value of iron indices in hemodialysis patients receiving epoetin. <i>Kidney International</i> , 2001, 60, 300-308.	5.2	23
99	Prospects for Dietary Therapy of Recurrent Nephrolithiasis. <i>Advances in Chronic Kidney Disease</i> , 2009, 16, 21-29.	1.4	23
100	Pharmacologic Treatment of Kidney Stone Disease. <i>Urologic Clinics of North America</i> , 2013, 40, 21-30.	1.8	23
101	The exposome for kidney stones. <i>Urolithiasis</i> , 2016, 44, 3-7.	2.0	22
102	Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study. <i>Clinical Trials</i> , 2004, 1, 451-460.	1.6	21
103	Stone Disease in Living-Related Renal Donors: Long-Term Outcomes for Transplant Donors and Recipients. <i>Journal of Endourology</i> , 2013, 27, 1520-1524.	2.1	21
104	Novel Cystine Ester Mimics for the Treatment of Cystinuria-induced Urolithiasis in a Knockout Mouse Model. <i>Urology</i> , 2014, 84, 1249.e9-1249.e15.	1.0	21
105	<sc>Cystine Diamides as </sc>-Cystine Crystallization Inhibitors for Cystinuria. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7293-7298.	6.4	21
106	The Healthy Hearts and Kidneys (HHK) study: Design of a 2 Å— 2 RCT of technology-supported self-monitoring and social cognitive theory-based counseling to engage overweight people with diabetes and chronic kidney disease in multiple lifestyle changes. <i>Contemporary Clinical Trials</i> , 2018, 64, 265-273.	1.8	21
107	Cystine Growth Inhibition Through Molecular Mimicry: a New Paradigm for the Prevention of Crystal Diseases. <i>Current Rheumatology Reports</i> , 2015, 17, 33.	4.7	20
108	Beverages, diet, and prevention of kidney stones. <i>American Journal of Kidney Diseases</i> , 1999, 33, 398-400.	1.9	19

#	ARTICLE	IF	CITATIONS
109	Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. <i>Kidney International</i> , 2008, 74, 1588-1595.	5.2	19
110	Effect of the MTHFR C677T and A1298C Polymorphisms on Survival in Patients With Advanced CKD and ESRD: A Prospective Study. <i>American Journal of Kidney Diseases</i> , 2009, 53, 779-789.	1.9	19
111	Effect of diet orange soda on urinary lithogenicity. <i>Urological Research</i> , 2012, 40, 237-241.	1.5	19
112	AA-type amyloidosis associated with non-Hodgkin's lymphoma: A case report. <i>Human Pathology</i> , 2004, 35, 1041-1044.	2.0	18
113	Laxative Abuse, Eating Disorders, and Kidney Stones: A Case Report and Review of the Literature. <i>American Journal of Kidney Diseases</i> , 2012, 60, 295-298.	1.9	18
114	Health Status and Quality of Life in Patients With Stable Coronary Artery Disease and Chronic Kidney Disease Treated With Optimal Medical Therapy or Percutaneous Coronary Intervention (Post Hoc) Tj ETQq0 0 0 rgBTd/Overload 10 Tf 50		
115	Hypothesis: Urbanization and exposure to urban heat islands contribute to increasing prevalence of kidney stones. <i>Medical Hypotheses</i> , 2015, 85, 953-957.	1.5	18
116	Personalized Intervention in Monogenic Stone Formers. <i>Journal of Urology</i> , 2018, 199, 623-632.	0.4	17
117	Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. <i>Rheumatology</i> , 2019, 58, 61-69.	1.9	17
118	The use of antibiotics and risk of kidney stones. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 311-315.	2.0	17
119	Cystinuria: an update on pathophysiology, genetics, and clinical management. <i>Pediatric Nephrology</i> , 2022, 37, 1705-1711.	1.7	17
120	The Absence of Rhabdomyolysis-induced Renal Failure Following the World Trade Center Collapse. <i>American Journal of Medicine</i> , 2002, 113, 260.	1.5	16
121	Have Advances in Extracorporeal Removal Techniques Changed the Indications for Their Use in Poisonings?. <i>Advances in Chronic Kidney Disease</i> , 2011, 18, 172-179.	1.4	16
122	Early Recognition and Management of Rare Kidney Stone Disorders. <i>Urologic Nursing</i> , 2018, 37, 81.	0.1	16
123	Comprehensive Genetic Analysis Reveals Complexity of Monogenic Urinary Stone Disease. <i>Kidney International Reports</i> , 2021, 6, 2862-2884.	0.8	15
124	The Older Adult Patient and Kidney Function. <i>The Consultant Pharmacist</i> , 2012, 27, 431-444.	0.4	14
125	Symptomatic Central Venous Stenosis in a Hemodialysis Patient Leading to Loss of Arteriovenous Access: A Case Report and Literature Review. <i>Nephron Extra</i> , 2014, 4, 50-54.	1.1	14
126	Assessment and misassessment of potassium, phosphorus, and protein in the hemodialysis diet. <i>Seminars in Dialysis</i> , 2018, 31, 479-486.	1.3	14



#	ARTICLE	IF	CITATIONS
127	Prevalence of low molecular weight proteinuria and Dent disease 1 CLCN5 mutations in proteinuric cohorts. <i>Pediatric Nephrology</i> , 2020, 35, 633-640.	1.7	14
128	Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup. <i>Critical Care</i> , 2021, 25, 201.	5.8	14
129	Nephrolithiasis. <i>Annals of Internal Medicine</i> , 2009, 151, ITC2.	3.9	13
130	Radioisotope blood volume measurement in hemodialysis patients. <i>Hemodialysis International</i> , 2014, 18, 406-414.	0.9	13
131	Treatment of calcium nephrolithiasis in the patient with hyperuricosuria. <i>Journal of Nephrology</i> , 2014, 27, 601-605.	2.0	13
132	Urine proteomic analysis in cystinuric children with renal stones. <i>Journal of Pediatric Urology</i> , 2015, 11, 217.e1-217.e6.	1.1	13
133	Effect of increasing doses of cystine-binding thiol drugs on cystine capacity in patients with cystinuria. <i>Urolithiasis</i> , 2019, 47, 549-555.	2.0	13
134	The Association of Mesalamine With Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 72-76.	1.4	13
135	Update on Uric Acid and the Kidney. <i>Current Rheumatology Reports</i> , 2022, 24, 132-138.	4.7	13
136	Hyperkalemia after the Publication of RALES. <i>New England Journal of Medicine</i> , 2004, 351, 2448-2450.	27.0	12
137	A Pilot Study of the Effect of Sodium Thiosulfate on Urinary Lithogenicity and Associated Metabolic Acid Load in Non-Stone Formers and Stone Formers with Hypercalciuria. <i>PLoS ONE</i> , 2013, 8, e60380.	2.5	12
138	Managing proteinâ€energy wasting in hemodialysis patients: A comparison of animalâ€and plantâ€based protein foods. <i>Seminars in Dialysis</i> , 2019, 32, 41-46.	1.3	12
139	Assessment of health-related quality of life in patients with cystinuria on tiopronin therapy. <i>Urolithiasis</i> , 2020, 48, 313-320.	2.0	12
140	Comparison of Selective Versus Empiric Pharmacologic Preventative Therapy With Kidney Stone Recurrence. <i>Urology</i> , 2021, 149, 81-88.	1.0	12
141	Plant-Based Milk Alternatives and Risk Factors for Kidney Stones and Chronic Kidney Disease. , 2022, 32, 363-365.		12
142	Taxi cab syndrome: a review of the extensive genitourinary pathology experienced by taxi cab drivers and what we can do to help. <i>Reviews in Urology</i> , 2014, 16, 99-104.	0.9	12
143	Sodium bicarbonate therapy for acute respiratory acidosis. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 223-230.	2.0	11
144	Acute Peritoneal Dialysis During the COVID-19 Pandemic at Bellevue Hospital in New York City. <i>Kidney360</i> , 2020, 1, 1345-1352.	2.1	11

#	ARTICLE	IF	CITATIONS
145	Reconsideration of the 1988 NIH Consensus Statement on Prevention and Treatment of Kidney Stones: Are the Recommendations Out of Date?. <i>Reviews in Urology</i> , 2002, 4, 53-60.	0.9	11
146	The Search for Monogenic Causes of Kidney Stones. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 507-510.	6.1	10
147	Nephrolithiasis in women. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 201-206.	2.0	10
148	Occupational kidney stones. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 232-236.	2.0	10
149	Feasibility and Acceptability of mHealth Interventions for Managing Hyperphosphatemia in Patients Undergoing Hemodialysis. , 2021, 31, 403-410.		10
150	Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia. <i>International Journal of Nephrology and Renovascular Disease</i> , 2010, 3, 1.	1.8	9
151	Medication adherence assessment in a clinical trial with centralized follow-up and direct-to-patient drug shipments. <i>Clinical Trials</i> , 2013, 10, 441-448.	1.6	9
152	Urine proteomic profiling in patients with nephrolithiasis and cystinuria. <i>International Urology and Nephrology</i> , 2019, 51, 593-599.	1.4	9
153	Effect of antibiotic treatment on <i>Oxalobacter formigenes</i> colonization of the gut microbiome and urinary oxalate excretion. <i>Scientific Reports</i> , 2021, 11, 16428.	3.3	9
154	Water to prevent kidney stones: tap vs bottled; soft vs hard “ does it matter?. <i>BJU International</i> , 2019, 124, 905-906.	2.5	8
155	Managing Hyperkalemia: Another Benefit of Exercise in People With Chronic Kidney Disease?. , 2020, 30, 380-383.		8
156	Extracorporeal Treatment for Methotrexate Poisoning. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 602-622.	4.5	8
157	Genetic Causes of Kidney Stones and Kidney Failure. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2012, 10, 2-18.	0.8	7
158	Differences in national and international guidelines regarding use of kidney stone formers as living kidney donors. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 140-147.	2.0	7
159	Early Recognition and Management of Rare Kidney Stone Disorders. <i>Urologic Nursing</i> , 2017, 37, 81-9, 102.	0.1	7
160	Economic implications of non-adherence to treatment recommendations for hemodialysis patients with anemia. <i>Dialysis and Transplantation</i> , 2006, 35, 660-671.	0.2	6
161	Refining Diagnostic Approaches in Nephrolithiasis: Incomplete Distal Renal Tubular Acidosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1380-1382.	4.5	6
162	Phosphate Additive Avoidance in Chronic Kidney Disease. <i>Diabetes Spectrum</i> , 2017, 30, 101-106.	1.0	6

#	ARTICLE	IF	CITATIONS
163	Vitamin D and Kidney Stones. <i>Urology</i> , 2020, 139, 1-7.	1.0	6
164	Urinary stone disease prevalence and associations in cystic fibrosis. <i>Urolithiasis</i> , 2021, 49, 415-423.	2.0	6
165	Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning. <i>Kidney International</i> , 2021, 100, 720-736.	5.2	6
166	Impact of mild chronic hyponatremia on falls, fractures, osteoporosis, and death. <i>American Journal of Orthopedics</i> , 2013, 42, 522-7.	0.7	6
167	Kidney Stones and the Risk of Coronary Heart Disease. <i>American Journal of Kidney Diseases</i> , 2013, 62, 1039-1041.	1.9	5
168	Monosodium Urate Stones Are Rare, and Urine pH Is Not Low in Cystinuria. <i>American Journal of Kidney Diseases</i> , 2013, 62, 179-180.	1.9	5
169	Evidence for inheritance of medullary sponge kidney. <i>Kidney International</i> , 2013, 83, 193-196.	5.2	5
170	Access to Care for VA Dialysis Patients During Superstorm Sandy. <i>Journal of Primary Care and Community Health</i> , 2019, 10, 215013271986359.	2.1	5
171	Challenging patient phenotypes in the management of anaemia of chronic kidney disease. <i>International Journal of Clinical Practice</i> , 2021, 75, e14681.	1.7	5
172	CLINICAL USE OF CYSTINE SUPERSATURATION MEASUREMENTS. <i>Journal of Urology</i> , 2000, , 1481-1485.	0.4	5
173	Comparison of Selective vs Empiric Pharmacologic Preventive Therapy of Kidney Stone Recurrence With High-Risk Features. <i>Urology</i> , 2022, 164, 74-79.	1.0	5
174	The Normal Saline Ceremony. <i>American Journal of Kidney Diseases</i> , 2010, 56, A28-A29.	1.9	4
175	Facilitating the transition from physiology to hospital wards through an interdisciplinary case study of septic shock. <i>BMC Medical Education</i> , 2014, 14, 78.	2.4	4
176	Institutional Characteristics Associated with Receipt of Emergency Care for Obstructive Pyelonephritis at Community Hospitals. <i>Journal of Urology</i> , 2015, 193, 851-856.	0.4	4
177	Opioid Overuse or NSAID Underuse? A Response to the Pain Guide. <i>American Journal of Kidney Diseases</i> , 2017, 69, 865.	1.9	4
178	Effect of thiazolidinedione therapy on the risk of uric acid stones. <i>Kidney International</i> , 2019, 95, 1022-1024.	5.2	4
179	Blood volume analysis as a guide for dry weight determination in chronic hemodialysis patients: a crossover study. <i>BMC Nephrology</i> , 2019, 20, 47.	1.8	4
180	Extracorporeal treatments for isoniazid poisoning: Systematic review and recommendations from the EXTRIP workgroup. <i>Pharmacotherapy</i> , 2021, 41, 463-478.	2.6	4

#	ARTICLE	IF	CITATIONS
181	Fomepizole for ethyleneglycol poisoning. Lancet, The, 1999, 354, 1646.	13.7	3
182	Nephrolithiasis complicating treatment of diabetes insipidus. Urological Research, 2005, 33, 244-246.	1.5	3
183	A New CJASN Feature. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 2.	4.5	3
184	Helicobacter pylori, Oxalobacter formigenes, and risk of kidney stones. Medical Hypotheses, 2015, 84, 601.	1.5	3
185	Recurrent Calcium Kidney Stones. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1388-1390.	4.5	3
186	Calcified Mass in a Patient on Long-Term Hemodialysis. New England Journal of Medicine, 1998, 338, 1427-1427.	27.0	2
187	Conversion of Chronic Hemodialysis Patients from Erythropoietin Alfa to Darbepoetin Alfa. Hospital Pharmacy, 2004, 39, 333-337.	1.0	2
188	Uric acid stones following hepatic transplantation. Urological Research, 2004, 32, 423-426.	1.5	2
189	Minimal Change Disease and IgA Deposition: Separate Entities or Common Pathophysiology?. Case Reports in Nephrology, 2013, 2013, 1-3.	0.4	2
190	Cocktail Party Nephrology. JAMA - Journal of the American Medical Association, 2013, 309, 2561.	7.4	2
191	Bilateral Tubulocystic Renal Cell Carcinomas in Diabetic End-Stage Renal Disease: First Case Report with Cytogenetic and Ultrastructural Studies. Rare Tumors, 2013, 5, 185-188.	0.6	2
192	Review: Thiazide, citrate, or allopurinol reduces recurrence after acute kidney stone episodes. Annals of Internal Medicine, 2013, 159, J12.	3.9	2
193	The Clinical Impact of Accurate Cystine Calculi Characterization Using Dual-Energy Computed Tomography. Case Reports in Radiology, 2015, 2015, 1-5.	0.3	2
194	Does Vitamin D Supplementation Cause Kidney Stones?. Journal of Urology, 2017, 197, 280-281.	0.4	2
195	Falsely elevated salicylate concentration in a patient with hypertriglyceridemia. Toxicology Communications, 2018, 2, 1-2.	0.7	2
196	Assessing the effect of extracorporeal treatments for lithium poisoning. British Journal of Clinical Pharmacology, 2021, 87, 214-215.	2.4	2
197	A Report of Two Cases: Unlearning Lactic Acidosis. Clinical Practice and Cases in Emergency Medicine, 2021, 2, 182-185.	0.3	2
198	Effects of ambient temperature and humidity on kidney stone admissions in Brazil. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2020, 42, 133-135.	0.9	2

#	ARTICLE	IF	CITATIONS
199	Patients at the center: in our practice, and in our use of language. ACP Journal Club, 2004, 140, A14.	0.1	2
200	Comparison of Empiric Preventative Pharmacologic Therapies on Stone Recurrence Among Patients with Kidney Stone Disease. Urology, 2022, 166, 111-117.	1.0	2
201	Chitosan does not reduce post-prandial urinary oxalate excretion. Urological Research, 2006, 34, 227-230.	1.5	1
202	109: Febuxostat in Gout: Serum Urate Responses in Uric Acid Overproducers vs. Underexcretors. American Journal of Kidney Diseases, 2010, 55, B59.	1.9	1
203	Response to "Chemistry misconceptions associated with understanding calcium and phosphate homeostasis"; American Journal of Physiology - Advances in Physiology Education, 2010, 34, 23-23.	1.6	1
204	New and emerging therapies for gout. Clinical Investigation, 2011, 1, 1563-1575.	0.0	1
205	Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients. Nephron Extra, 2011, 1, 212-216.	1.1	1
206	MP25-14 KIDNEY STONES ARE A RISK FACTOR FOR CKD AND ESRD. Journal of Urology, 2014, 191, .	0.4	1
207	In Reply to "Role of Sodium Restriction in Recurrent Stone Formers With Hyperoxaluria". American Journal of Kidney Diseases, 2014, 64, 478-479.	1.9	1
208	Dysphoria Induced in Dialysis Providers by Secondary Hyperparathyroidism. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 9-11.	4.5	1
209	Editorial. Current Opinion in Nephrology and Hypertension, 2020, 29, 199-200.	2.0	1
210	Are conventional stone analysis techniques reliable for the identification of 2,8-dihydroxyadenine kidney stones? A case series. Urolithiasis, 2020, 48, 337-344.	2.0	1
211	Metabolic Investigations: When and in Whom. , 2010, , 659-665.		1
212	Editorial: Controversies in nephrologic covidology. Current Opinion in Nephrology and Hypertension, 2021, 30, 173-175.	2.0	1
213	Patients at the center: in our practice, and in our use of language. ACP Journal Club, 2004, 140, A14; author reply A14-5.	0.1	1
214	Positive Predictive Value of Fecal Occult Blood Testing in Asymptomatic Average-Risk Patients with Varying Degrees of Chronic Kidney Disease. Gastrointestinal Endoscopy, 2006, 63, AB201.	1.0	0
215	Homocysteine Lowering and Severe Kidney Disease"Reply. JAMA - Journal of the American Medical Association, 2008, 299, .	7.4	0
216	Future Directions in Nephrolithiasis Research. Advances in Chronic Kidney Disease, 2009, 16, 3-4.	1.4	0

#	ARTICLE	IF	CITATIONS
217	The Hemodialysis Machine: Where the Nephrologists and Toxicologists Meet. <i>Advances in Chronic Kidney Disease</i> , 2011, 18, 157-159.	1.4	0
218	Capital Punishment: What Is the Appropriate Abbreviation for Partial Pressure of a Gas?. <i>American Journal of the Medical Sciences</i> , 2012, 344, 255-256.	1.1	0
219	842 ADMINISTRATION OF A UNIQUE RENOPROTECTIVE COCKTAIL IN A RAT MODEL: CAN WARM ISCHEMIA-REPERFUSION INJURY BE PREVENTED?. <i>Journal of Urology</i> , 2012, 187, .	0.4	0
220	2302 CYSTINE ANALOGS AS POTENTIAL THERAPEUTIC AGENTS FOR CYSTINURIA. <i>Journal of Urology</i> , 2012, 187, .	0.4	0
221	1843 MANAGEMENT OF CYSTINURIC PATIENTS IN A DEDICATED STONE CLINIC DECREASES STONE EVENTS. <i>Journal of Urology</i> , 2012, 187, .	0.4	0
222	2256 CLINICAL VALIDATION OF A NOVEL ASSAY USED FOR MONITORING TREATMENT OF PATIENTS WITH CYSTINURIA. <i>Journal of Urology</i> , 2012, 187, .	0.4	0
223	2107 PATHOPHYSIOLOGICAL BASES OF INTRA-RENAL CALCIFICATION IN MICE DEFICIENT FOR TAMM-HORSFALL PROTEIN (UROMODULIN). <i>Journal of Urology</i> , 2013, 189, .	0.4	0
224	Zero Dark Thirty: A Nephrologist at the Movies. <i>American Journal of Kidney Diseases</i> , 2014, 63, A20-A22.	1.9	0
225	MP34-16 PATIENTS WITH CYSTINURIA HAVE ALKALINE URINE DUE TO RENAL LOSS OF SULFATE PRECURSORS. <i>Journal of Urology</i> , 2015, 193, .	0.4	0
226	Editorial. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 128-129.	2.0	0
227	Bariatric surgery in a patient with cystinuria. <i>Clinical Nephrology Case Studies</i> , 2021, 9, 54-58.	0.7	0
228	Dietary Inflammatory Index and Cardiovascular Disease Risk Factors in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Current Developments in Nutrition</i> , 2021, 5, 412.	0.3	0
229	Cystinuria: Assessing and Managing Risk. , 2014, , 105-114.		0
230	Nephrolithiasis in the Elderly. , 2019, , 201-212.		0
231	Nutritional prevention and treatment of urinary tract stones. , 2022, , 685-697.		0
232	Case Study - Case Studies in Cystinuria. <i>Urologic Nursing</i> , 2017, 37, 90-3.	0.1	0
233	Editorial: New perspectives on estimated glomerular filtration rate and health equity. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 157-159.	2.0	0
234	How life imitates baseball. <i>The Pharos of Alpha Omega Alpha-honor Medical Society Alpha Omega Alpha</i> , 2004, 67, 34-5.	0.1	0

#	ARTICLE	IF	CITATIONS
235	Metabolic Evaluation and Prevention of Renal Stone Disease. , 0, , 642-650.		0